Keeping FDA reform talks alive

WASHINGTON - Despite dwindling prospects for major FDA reform efforts by Congress, legislative and administrative maneuverings continue to keep alive prospects for continued changes in the regulatory framework this year.

The potential exists to expand the agenda for administrative reform, as the agency and biotech industry leaders begin to discuss procedural changes that would directly benefit emerging companies engaged in early-stage product development...